Clinical Trial Update: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 study of Lanadelumab (SHP643) in Chinese participants with hereditary angioedema has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Lanadelumab (SHP643) (Lanadelumab)

Snippet

Sponsor: Takeda | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2024-12-13